GLG Research StudySM: 245 Neurologists on Tysabri for Multiple Sclerosis
A GLG Research Study of 245 U.S.-based neurologists about their opinion of Tysabri for the treatment of multiple sclerosis, given continuing occurrences of progressive multifocal leukoencephalopathy (PML), and the FDA's warning that incidence of PML increases with duration of Tysabri therapy.
Read the full report:
About GLG Research Studies
GLG Research Studies are surveys and other reports, powered by the unique expertise available in the GLG CouncilsSM and by other relationships that Gerson Lehrman Group has developed. Studies are built on a foundation of survey-style expert insights gathered through GLG's Q&A platform. They are typically authored by GLG Council MembersSM who help create the questions, moderate the completion of the study, and provide expert analysis, insight extraction, and synthesis of the results. GLG Research Studies are available for purchase. GLG clients can commission custom reports by developing unique survey questions for GLG Council Member populations. Contact GLG for more information.
GLG Research Studies are solely the work of the respondents and have not been edited or endorsed by GLG.